Randomized controlled trial evaluating synbiotic supplementation as an adjuvant therapy in the treatment of Parkinson’s disease
Inflammopharmacology · 2025-07 · 33 (7) · 3897-3908
DOI: 10.1007/s10787-025-01752-8 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Inflammopharmacology, online erschienen am 28.05.2025. Verfasst von Mohamed E Ramadan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, Tanta, 31111, Egypt. mohamed_ehab@pharm.tanta.edu.eg. Hauptthemen laut MEDLINE: Antiparkinson Agents, Carbidopa, Levodopa, Parkinson Disease. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tanta University.
Abstract (Originalsprache)
Background and aim Neuroinflammatory mechanisms have been closely related to the microbiota-gut-brain axis and could lead to degeneration of dopaminergic neurons with subsequent development and progression of Parkinson’s disease (PD). Targeting this pathway for the treatment of PD has sparked a lot of interest. Hence, this study investigates the therapeutic potential of a synbiotic supplement, in conjunction with l -dopa for the management of PD.
Methods
This randomized controlled trial enrolled 66 Parkinson's disease patients, who were randomly assigned to two groups: a control group ( n = 33) receiving standard l -dopa/carbidopa (100/25 mg) therapy three times daily for three months, and a synbiotic group ( n = 33) receiving the same l -dopa/carbidopa regimen with two sachets of the synbiotic supplement daily for three months. The outcome measures included assessment of Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and serum levels of tumor necrosis factor-alpha (TNF-α), malondialdehyde (MDA), brain-derived neurotrophic factor (BDNF), and α-synuclein (α-Syn). Blood samples were collected from all patients for biomarker analysis in serum.
Results
Three months after intervention, the synbiotic group demonstrated significantly greater improvement in motor and non-motor symptoms compared to the control group evidenced by the change in the scores of each part of the MDS-UPDRS. Concurrently, the synbiotic group exhibited significantly lower serum levels of pro-inflammatory marker TNF-α and oxidative stress marker MDA, and significantly higher levels of the neuroprotective factor BDNF.
Conclusion
Supplementing with synbiotics exhibits promising neuroprotective and therapeutic effects in the treatment of Parkinson’s disease patients. Clinicaltrials.gov registration number NCT05576818. Retrospectively registered in October 2022.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, Tanta, 31111, Egypt. mohamed_ehab@pharm.tanta.edu.eg.
- Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, Tanta, 31111, Egypt.
- Neuropsychiatry Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Förderung
- Tanta University
Zitieren
APA
Ramadan, M. E., Mostafa, T. M., Ghali, A. A., & El-Afify, D. R. (2025). Randomized controlled trial evaluating synbiotic supplementation as an adjuvant therapy in the treatment of Parkinson’s disease. Inflammopharmacology, 33(7), 3897-3908. https://doi.org/10.1007/s10787-025-01752-8
Vancouver
Ramadan ME, Mostafa TM, Ghali AA, El-Afify DR. Randomized controlled trial evaluating synbiotic supplementation as an adjuvant therapy in the treatment of Parkinson’s disease. Inflammopharmacology. 2025;33(7):3897-3908. doi:10.1007/s10787-025-01752-8
BibTeX
@article{Ramadan2025,
author = {Ramadan, Mohamed E and Mostafa, Tarek M and Ghali, Azza A and El-Afify, Dalia R},
title = {Randomized controlled trial evaluating synbiotic supplementation as an adjuvant therapy in the treatment of Parkinson’s disease},
journal = {Inflammopharmacology},
year = {2025},
volume = {33},
number = {7},
pages = {3897--3908},
doi = {10.1007/s10787-025-01752-8}
}
EUVIMED